Trained immunity provides a unifying framework linking innate immune memory to both protective and maladaptive inflammation ...

An international study that pooled brain scans and memory tests from thousands of adults has shed new light on how structural ...

The U.S. Food and Drug Administration has approved Itvisma (onasemnogene abeparvovec-brve) for the treatment of spinal muscular atrophy (SMA) in patients 2 years and older with confirmed mutation in ...

What Is Itvisma, and Why Does It Matter? Itvisma (onasemnogene abeparvovec-brve) is a gene therapy that the FDA has approved to treat spinal muscular atrophy (SMA) in adults, teens, and children 2 or ...

Novartis secured approval for its drug to treat certain patients diagnosed with spinal muscular atrophy from the Food and Drug Administration. Itvisma, or onasemnogene abeparvovec-brve, was approved ...

Geographic atrophy, an advanced form of dry age-related macular degeneration, leaves almost five million people around the world nearly blind. A new clinical study provides a possible solution that ...

Geographic atrophy due to age-related macular degeneration (AMD) is the leading cause of irreversible blindness and affects more than 5 million persons worldwide. No therapies to restore vision in ...

Mary is the bedrock of her family. “She’s the one we all go to,” says her son Eric. “She’s selfless, extremely sweet, very personable—but she can also be very feisty.” So when she returned from an eye ...

The earlier patients with potentially blinding geographic atrophy start treatment with the complement inhibitor pegcetacoplan, the more retinal tissue they retain 4 years later compared with patients ...

Vitamin supplements known to potentially slow the progression of intermediate age-related macular degeneration do not seem to have a similar effect on geographic atrophy, an advanced form of the dry ...